Tags

Type your tag names separated by a space and hit enter

HOXD-AS1: a novel oncogenic long intergenic non-coding RNA in humans.

Abstract

OBJECTIVE

Long non-coding RNAs are an emerging special class of regulatory RNAs with more than 200 nucleotides that play vital roles in gene regulation, metabolism, drug resistance, cell differentiation, and other processes. These RNAs were also reported to be dysregulated in human disease, especially malignant tumors. However, the underlying mechanisms remain elusive. HOXD cluster antisense RNA 1 (HOXD-AS1), a recently discovered long non-coding RNA, is overexpressed in many cancers. We now review recent advances in understanding the function, role, regulation, and oncogenic properties of HOXD-AS1.

MATERIALS AND METHODS

A systematic literature review in PubMed of HOXD-AS1 and cancer-related articles in English, published until June 2018, was conducted.

RESULTS

The literature suggests that HOXD-AS1 is an oncogene that regulates diverse physiological and cellular processes such as proliferation, apoptosis, migration, invasion, metastasis, chemoresistance, epithelial to mesenchymal transition, and stem cell formation by interacting with various regulatory proteins and sequestering several microRNAs such as miR-608, miR-130a, and miR-217.

CONCLUSIONS

HOXD-AS1 may be a prognostic biomarker and potential therapeutic target for various tumor diagnosis and treatment.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Hepatobiliary Surgery, Haikou People's Hospital/Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou, Hainan, P.R. China. dryyj@163.com.

    , , , ,

    Source

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    31002165

    Citation

    Xie, S C., et al. "HOXD-AS1: a Novel Oncogenic Long Intergenic Non-coding RNA in Humans." European Review for Medical and Pharmacological Sciences, vol. 23, no. 7, 2019, pp. 2898-2907.
    Xie SC, Yang YJ, Zhang JQ, et al. HOXD-AS1: a novel oncogenic long intergenic non-coding RNA in humans. Eur Rev Med Pharmacol Sci. 2019;23(7):2898-2907.
    Xie, S. C., Yang, Y. J., Zhang, J. Q., Zhou, S., Xie, S. W., & Hua, Y. Y. (2019). HOXD-AS1: a novel oncogenic long intergenic non-coding RNA in humans. European Review for Medical and Pharmacological Sciences, 23(7), pp. 2898-2907. doi:10.26355/eurrev_201904_17568.
    Xie SC, et al. HOXD-AS1: a Novel Oncogenic Long Intergenic Non-coding RNA in Humans. Eur Rev Med Pharmacol Sci. 2019;23(7):2898-2907. PubMed PMID: 31002165.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - HOXD-AS1: a novel oncogenic long intergenic non-coding RNA in humans. AU - Xie,S C, AU - Yang,Y J, AU - Zhang,J Q, AU - Zhou,S, AU - Xie,S W, AU - Hua,Y Y, PY - 2019/4/20/entrez SP - 2898 EP - 2907 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 23 IS - 7 N2 - OBJECTIVE: Long non-coding RNAs are an emerging special class of regulatory RNAs with more than 200 nucleotides that play vital roles in gene regulation, metabolism, drug resistance, cell differentiation, and other processes. These RNAs were also reported to be dysregulated in human disease, especially malignant tumors. However, the underlying mechanisms remain elusive. HOXD cluster antisense RNA 1 (HOXD-AS1), a recently discovered long non-coding RNA, is overexpressed in many cancers. We now review recent advances in understanding the function, role, regulation, and oncogenic properties of HOXD-AS1. MATERIALS AND METHODS: A systematic literature review in PubMed of HOXD-AS1 and cancer-related articles in English, published until June 2018, was conducted. RESULTS: The literature suggests that HOXD-AS1 is an oncogene that regulates diverse physiological and cellular processes such as proliferation, apoptosis, migration, invasion, metastasis, chemoresistance, epithelial to mesenchymal transition, and stem cell formation by interacting with various regulatory proteins and sequestering several microRNAs such as miR-608, miR-130a, and miR-217. CONCLUSIONS: HOXD-AS1 may be a prognostic biomarker and potential therapeutic target for various tumor diagnosis and treatment. SN - 2284-0729 UR - https://www.unboundmedicine.com/medline/citation/31002165/HOXD-AS1:_a_novel_oncogenic_long_intergenic_non-coding_RNA_in_humans L2 - https://www.europeanreview.org/article/17568 DB - PRIME DP - Unbound Medicine ER -